BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 25573156)

  • 1. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.
    Long PM; Tighe SW; Driscoll HE; Fortner KA; Viapiano MS; Jaworski DM
    J Cell Physiol; 2015 Aug; 230(8):1929-43. PubMed ID: 25573156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
    Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM
    Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells.
    Long PM; Tighe SW; Driscoll HE; Moffett JR; Namboodiri AM; Viapiano MS; Lawler SE; Jaworski DM
    PLoS One; 2013; 8(11):e80714. PubMed ID: 24278309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells.
    Long PM; Moffett JR; Namboodiri AMA; Viapiano MS; Lawler SE; Jaworski DM
    J Biol Chem; 2013 Sep; 288(36):26188-26200. PubMed ID: 23884408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
    Zhu TZ; Li XM; Luo LH; Song ZQ; Gao X; Li ZQ; Su JY; Liang GB
    Int J Oncol; 2014 Aug; 45(2):699-709. PubMed ID: 24841897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.
    Miyazaki T; Pan Y; Joshi K; Purohit D; Hu B; Demir H; Mazumder S; Okabe S; Yamori T; Viapiano M; Shin-ya K; Seimiya H; Nakano I
    Clin Cancer Res; 2012 Mar; 18(5):1268-80. PubMed ID: 22230766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.
    Kostopoulou ON; Mohammad AA; Bartek J; Winter J; Jung M; Stragliotto G; Söderberg-Nauclér C; Landázuri N
    Int J Cancer; 2018 Mar; 142(6):1266-1276. PubMed ID: 29067692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.
    Spina R; Voss DM; Asnaghi L; Sloan A; Bar EE
    Oncotarget; 2016 Jan; 7(1):459-72. PubMed ID: 26575950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells.
    Kuramoto K; Yamamoto M; Suzuki S; Sanomachi T; Togashi K; Seino S; Kitanaka C; Okada M
    FEBS J; 2020 May; 287(10):2023-2036. PubMed ID: 31868973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells.
    Iglesia RP; Prado MB; Cruz L; Martins VR; Santos TG; Lopes MH
    Stem Cell Res Ther; 2017 Apr; 8(1):76. PubMed ID: 28412969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell signature in glioblastoma: therapeutic development for a moving target.
    Nakano I
    J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
    Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
    Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species.
    Gersey ZC; Rodriguez GA; Barbarite E; Sanchez A; Walters WM; Ohaeto KC; Komotar RJ; Graham RM
    BMC Cancer; 2017 Feb; 17(1):99. PubMed ID: 28160777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
    Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
    J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
    Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
    Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
    Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
    Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
    Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.